title: [Use of cyclosporine 0.05% in various ocular surface disorders].
abstract: It is proved that chronic ocular surface inflammatory disease (including allergic blepharitis, recurrent chalyazia, punctuate keratitis, recurrent herpetic corneal erosions, late stages of adenoviral keratoconjunctivitis, etc.) takes part in the development of secondary dry eye syndrome (DES). However, therapies for inflammation-induced impairment of tear production do not provide long-term control of inflammatory process. Cyclosporine 0.05% eye drops are an option. Their effect is well-studied in foreign practice. Local application experience of cyclosporine 0.05% eye drops was summarized at a meeting of the Russian expert group on DES and conclusions were made on their effectiveness in treatment of dry eye syndrome associated with certain ocular surface inflammatory disorders, such as allergic blepharoconjunctivitis, late stages of adenoviral keratoconjunctivitis, and others.
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Maĭchuk
authors.forename: O A
authors.initials: OA
authors.lastname: Vasil'eva
authors.forename: M M
authors.initials: MM
authors.lastname: Shokirova
mesh_terms: D000818:Animals; D001762:Blepharitis / Q000150:complications* / Q000188:drug therapy; D003233:Conjunctivitis, Allergic / Q000150:complications* / Q000188:drug therapy; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007639:Keratoconjunctivitis, Infectious / Q000150:complications* / Q000188:drug therapy; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D009883:Ophthalmic Solutions; D016572:Cyclosporine